Lantheus Holdings

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lantheus reports record revenues in 2022, eyes sustained growth

Lantheus' strong financial performance and market leadership position it well for continued growth.
While facing competition and investment challenges, Lantheus is focused on innovation and market expansion.
The company's strategic acquisitions, pipeline expansion, and guidance for 2023 signal a positive outlook.
Lantheus aims to maintain profitability while investing in key areas for future growth and market leadership.

Lantheus Holdings reports record Q1 results and eyes oncology growth

Lantheus Holdings delivered robust Q1 results driven by key products, with strong revenue and margin performance.
The company's strategic acquisitions and pipeline advancements position them well for future growth in oncology and Alzheimer's diagnostics.
While facing challenges with certain programs and undisclosed cancer types, Lantheus has outlined clear opportunities for market expansion and new treatment avenues.

Lantheus Holdings excels in Q2, eyes European expansion and innovation

Lantheus Holdings delivered robust Q2 2023 results, showcasing strong revenue growth and operational impact, with raised guidance reflecting confidence in sustained performance.
The company's focus on differentiation, market leadership, and strategic partnerships positions it well for growth despite competitive and regulatory challenges.
Opportunities in expanding market reach, diversification through radiotherapeutic candidates, and product innovation present avenues for future growth and market dominance.
Navigating challenges in competition, regulatory changes, and supply chain optimization will be crucial for Lantheus to maintain its market-leading position and drive continued success.

Lantheus Holdings excels in Q3 with strong revenue growth and market leadership

Lantheus Holdings' strong Q3 performance, driven by robust revenue growth and strategic advancements, positions the company well for future success. Despite challenges such as fixed costs and seasonal fluctuations, Lantheus remains focused on leveraging opportunities in the growing radiopharmaceutical market. With a leading market share, innovative pipeline, and solid financial position, Lantheus is poised for continued growth and value creation.

Lantheus Holdings achieves record revenues, eyes growth in radiopharmaceuticals

Lantheus Holdings delivered strong financial performance in 2023 with record revenues and growth.
The company is strategically positioned to capitalize on opportunities in radiopharmaceuticals and oncology.
Challenges include managing potential product transitions and maintaining market leadership.
Overall, Lantheus shows promise for continued growth and innovation in the healthcare sector.

Lantheus Holdings excels in Q1 2024, eyes $1B sales

Lantheus Holdings delivered a strong performance in Q1 2024, driven by robust sales of PYLARIFY and operational excellence, showcasing financial strength and profitability.
The company's focus on innovation, strategic partnerships, and pipeline opportunities positions it well for future growth and market leadership in radioligand therapy.
While facing challenges in a competitive landscape and evolving industry dynamics, Lantheus has opportunities for revenue growth, market expansion, and strategic collaborations to drive long-term success.

Lantheus Holdings excels in Q2 with strong sales and strategic acquisitions

Lantheus Holdings delivered strong financial performance in Q2 2024, driven by PYLARIFY's robust sales and strategic acquisitions strengthening their pipeline.
Despite facing challenges such as regulatory uncertainties and market competition, Lantheus remains well-positioned for growth and market leadership.
With a focus on innovation, market leadership, and strategic acquisitions, Lantheus is poised to capitalize on opportunities in the radiopharmaceutical market and drive sustained growth.

Lantheus Holdings reports robust Q3 performance amidst market opportunities

Lantheus Holdings (LNTH) delivered a strong performance in Q3 2024, driven by key products and revenue growth.
The company faces challenges in navigating market uncertainties and maintaining growth momentum.
Opportunities lie in expanding market presence, capitalizing on reimbursement changes, and advancing Alzheimer's diagnostics.
Overall, Lantheus Holdings shows promise for future growth and innovation in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Cadence Design Systems

Cavco Industries

Perion Network

Here are four top-ranked liquid stocks, Cadence Design Systems (CDNS), Lantheus (LNTH), Cavco (CVCO) and Perion Network (PERI), which investors can add to their portfolio for returns.

Snap Up These 4 Top-Ranked Liquid Stocks for Solid Gains

Lantheus Holdings (LNTH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Lantheus Holdings, Inc. (LNTH) Hits Fresh High: Is There Still Room to Run?

Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q2 2022 Earnings Conference Call August 4, 2022 8:08 AM ET Company Participants Mark Kinarney - Senior Director, Investor Relations Mary Heino - President and Chief Executive Officer Robert Marshall - Chief Financial Officer and Treasurer Paul Blanchfield - Chief Commercial Officer Conference Call Participants Richard Newitter - Truist Company Zach Weiner - Jefferies Roanna Ruiz - SVB Securities Larry Solow - CJS Securities Anthony Petrone - Mizuho Securities Operator Good morning, ladies and gentlemen. Welcome to the Lantheus Second Quarter 2022 Conference Call.

Lantheus Holdings, Inc. (LNTH) CEO Mary Heino on Q2 2022 Results - Earnings Call Transcript

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 27.14% and 9.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Lantheus Holdings (LNTH) Q2 Earnings and Revenues Top Estimates

CONSOL Energy

Helmerich & Payne

Nabors Industries

PBF Energy

Patterson-UTI Energy

Range Resources

Talos Energy Inc

If you're just looking at the big S&P 500 energy stocks to make you money this year, you're missing out on some off-the-radar gains. The post 10 Off-The-Radar Stocks Are Quietly Making Investors Big Money appeared first on Investor's Business Daily.

10 Off-The-Radar Stocks Are Quietly Making Investors Big Money

Catalent

HEICO

Eli Lilly

Cheniere Energy

New Fortress Energy

Ollie's Bargain Outlet Hlds

Quanta Services

UnitedHealth Group

Vertex Pharmaceuticals

With earnings due, IBD Leaderboard stocks like Eli Lilly, Vertex and Ollie's test bases, breakouts and buy zones. The post Watch These Leaders With Earnings Due, Buy Zones In Focus appeared first on Investor's Business Daily.

Watch These Leaders With Earnings Due, Buy Zones In Focus

Skyline Corp.

U.S. Silica Holdings

Here are four top-ranked liquid stocks, Lantheus (LNTH), Skyline (SKY), CTS (CTS) and U.S. Silica Holdings (SLCA), which investors can add to their portfolio for solid returns.

4 Top-Ranked Liquid Stocks to Boost Portfolio Returns in 2022

Lantheus Holdings (LNTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

What Makes Lantheus Holdings (LNTH) a Good Fit for "Trend Investing"

Lantheus Holdings, Inc. (LNTH) Hit a 52 Week High, Can the Run Continue?

NORTH BILLERICA, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 4, 2022, to discuss its financial and operating results for the second quarter of 2022.

Lantheus Holdings to Host Second Quarter 2022 Earnings Conference Call and Webcast on August 4, 2022, at 8:00 a.m. Eastern Time

Agilysys

Here are four top-ranked liquid stocks, Lantheus (LNTH), Skyline (SKY), CTS (CTS) and Agilysys (AGYS), which investors can add to their portfolio for solid returns.

Snap Up These 4 Top-Ranked Liquid Stocks for Strong Gains

Dollar Tree

Marathon Petroleum

DLTR, MPC and LNTH made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 13, 2022.

Best Growth Stocks to Buy for July 13th

Which of the healthcare producers of Diagnostic Solutions is now a better buy to help build your portfolio's near-term capital value? Near-term only, repetition provides long term. Here find out what the best-informed, big-$ investors now think is likely to happen (good and bad) in the next 3+ months to prices of several stocks now seen.

Lantheus Holdings Rules The Medical Diagnostics Business World

Dottie Barr Promoted to Senior Vice President, Manufacturing and Technical Operations Dottie Barr Promoted to Senior Vice President, Manufacturing and Technical Operations

Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer

After losing some value lately, a hammer chart pattern has been formed for Lantheus Holdings (LNTH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Lantheus Holdings (LNTH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Study Results Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting Study Results Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Lantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imaging Agent, to Assess PD-L1 Expression for Immunotherapy in Cancer

Study Results Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Vancouver Study Results Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Vancouver

Lantheus' PYLARIFY AI™ Platform Demonstrates Higher Efficiency and Consistency While Maintaining Accuracy for Assessment of PSMA Imaging in Prostate Cancer

The average of price targets set by Wall Street analysts indicates a potential upside of 26.6% in Lantheus Holdings (LNTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Lantheus Holdings (LNTH)? Wall Street Analysts Think 27%

Builders FirstSource

CF Industries Holdings

Cenovus Energy

ICL-Israel Chemicals

Sociedad Quimica Y Minera De Chile

Encore Wire

These aren't likely the stocks you think about when you think about hot stocks, but that's what makes them so special. The post 7 Hot Stocks to Buy During the Next Market Crash appeared first on InvestorPlace.

7 Hot Stocks to Buy During the Next Market Crash

NORTH BILLERICA, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announced the following presentations at the upcoming 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Meeting, which will be held June 11-14, 2022 in Vancouver, BC, Canada.

Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

The consensus price target hints at a 44.2% upside potential for Lantheus Holdings (LNTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 44% Upside in Lantheus Holdings (LNTH): Here's What You Should Know

Lantheus Outlines Sustainable and Profitable Growth Strategy; Introduces Long-Term Financial Targets Lantheus Outlines Sustainable and Profitable Growth Strategy; Introduces Long-Term Financial Targets

Lantheus Hosts Inaugural Investor Day

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Lantheus Holdings (LNTH) Just Overtook the 20-Day Moving Average

If you are looking for stocks that are well positioned to maintain their recent uptrend, Lantheus Holdings (LNTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Lantheus Holdings (LNTH) Is a Great Choice for "Trend" Investors, Here's Why

Retrospective analysis demonstrates reliability of PSMA scan indices as response-imaging biomarker to androgen therapy in prostate cancer Retrospective analysis demonstrates reliability of PSMA scan indices as response-imaging biomarker to androgen therapy in prostate cancer

News for Lantheus Holdings Stock (LNTH)